Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene Effect on Beta-Amyloid and ApoE in Healthy Subjects
NCT02061878Phase 1Completed
- Sponsor
- ReXceptor Inc.
- Start
- Aug 2014
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bexarotene with Placebo (2 arms). Primary endpoint: Area under the effect curve for newly generated beta-Amyloid (clearance phase). Started Aug 2014; status: completed.
02
Drugs
bexarotene
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02061878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061878.